A once-promising vaccine for AIDS may have inadvertently increased the infection risk of people participating in clinical trials, researchers said on Wednesday.
The multinational trials involving more than 3,000 HIV-negative volunteers were canceled last month after a large-scale study found it was not effective at preventing infection.
Further analysis showed that those who received the vaccine had a higher rate of infection than those who received a placebo, said US pharmaceutical giant Merck, which helped develop the vaccine.
The study volunteers who received the vaccine are being advised of their potentially increased susceptibility, Merck said.
"We are analyzing the data to try to determine if the results are due to immune responses induced by the vaccine, differences in study populations, or some other biological phenomenon we don't yet understand, or simply due to chance," said Keith Gottesdiener, vice president of Merck's vaccine and infectious disease clinical research.
"It will take some time before we understand why the vaccine did not work and why there was a trend toward more cases of infection in volunteers who received the vaccine," he said in a statement.
The experimental vaccine cannot cause infection, Merck said.
It was a modified cold virus used to deliver three synthetically produced HIV genes in the hopes of stimulating a response from the immune system.
Unlike earlier failed vaccines which tried to get the immune system to produce antibodies, the V520 vaccine stimulated T cells, the main disease fighters of the body.
These are the cells that HIV infects and uses to replicate itself, leading to a drop in the number of T cells available to fight off other infections.
It's possible that the volunteers became more vulnerable to HIV infection because the vaccine stimulates an increase in the production of T cells, a spokeswoman said.
The randomized, double-blind trials were conducted in various sites in the US, Canada, Peru, Brazil, Dominican Republic, Haiti, Puerto Rico, Jamaica, Australia and South Africa beginning in 2004.
Volunteers, who were already at high-risk of contracting AIDS, were given prevention counseling in addition to the vaccine or placebo. But dozens became infected anyway.
All but one of the infections among those given the vaccine were in male volunteers and the bulk of those infected were homosexual men.
Those with a higher level of pre-existing immunity to the modified cold virus used to deliver the vaccine were twice as likely to have been infected if they received the vaccine.
The initial analysis found 21 cases of HIV infection among the 392 men who received the vaccine while only nine cases were reported among the 386 men with a high level of pre-existing immunity who were given a placebo.
The results are "both disappointing and puzzling," said Anthony Fauci, the director of the US National Institute of Allergy and Infectious Diseases, which co-sponsored the trials.
"Certainly, the failure of this HIV vaccine product was unexpected," he said in a statement.
"But this setback should not and can not diminish our commitment to developing an effective HIV vaccine."
About 12,000 people become infected with HIV every day and vaccines have historically been the most effective tool against infections diseases like polio and smallpox.
While scientists work on developing a vaccine, politicians need to implement proven prevention methods, Fauci said.
Russia and Ukraine have exchanged prisoners of war in the latest such swap that saw the release of hundreds of captives and was brokered with the help of the United Arab Emirates (UAE), officials said on Monday. Ukrainian President Volodymyr Zelenskiy said that 189 Ukrainian prisoners, including military personnel, border guards and national guards — along with two civilians — were freed. He thanked the UAE for helping negotiate the exchange. The Russian Ministry of Defense said that 150 Russian troops were freed from captivity as part of the exchange in which each side released 150 people. The reason for the discrepancy in numbers
A shark attack off Egypt’s Red Sea coast killed a tourist and injured another, authorities said on Sunday, with an Italian Ministry of Foreign Affairs source identifying both as Italian nationals. “Two foreigners were attacked by a shark in the northern Marsa Alam area, which led to the injury of one and the death of the other,” the Egyptian Ministry of Environment said in a statement. A source at the Italian foreign ministry said that the man killed was a 48-year-old resident of Rome. The injured man was 69 years old. They were both taken to hospital in Port Ghalib, about 50km north
‘MAGA CIVIL WAR’: Former Trump strategist Bannon said the H1-B program created ‘indentured servants,’ but Musk said that he was willing ‘to go to war on this issue’ US president-elect Donald Trump on Saturday weighed in on a bitter debate dividing his traditional supporters and tech barons such as Elon Musk, saying that he backs a special visa program that helps highly skilled workers enter the country. “I’ve always liked the [H1-B] visas, I have always been in favor of the visas, that’s why we have them” at Trump-owned facilities, he told the New York Post in his first public comments on the matter since it flared up this week. An angry back-and-forth, largely between Silicon Valley’s Musk and traditional anti-immigration Trump backers, has erupted in fiery fashion, with Musk
The foreign ministers of Germany, France and Poland on Tuesday expressed concern about “the political crisis” in Georgia, two days after Mikheil Kavelashvili was formally inaugurated as president of the South Caucasus nation, cementing the ruling party’s grip in what the opposition calls a blow to the country’s EU aspirations and a victory for former imperial ruler Russia. “We strongly condemn last week’s violence against peaceful protesters, media and opposition leaders, and recall Georgian authorities’ responsibility to respect human rights and protect fundamental freedoms, including the freedom to assembly and media freedom,” the three ministers wrote in a joint statement. In reaction
RSS